We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Baxter Plans NDA for Blood Disorder Drug After Phase III Positive Results
Baxter Plans NDA for Blood Disorder Drug After Phase III Positive Results
Baxter said Wednesday that its Bax 111 treatment for Von Willebrand disease met its primary endpoint in a pivotal clinical trial, setting it up for NDA filing later this year.